| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/17/2002 | WO2001054672A3 Closure of bacterial ghosts |
| 01/17/2002 | WO2001052791A3 Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents |
| 01/17/2002 | WO2001049722A3 New actinobacillus pleuropneumoniae outer membrane protein and its uses |
| 01/17/2002 | WO2001049320A3 Use of hemicellulose microparticles as vaccine adjuvant |
| 01/17/2002 | WO2001047543A3 Activation and inhibition of the immune system |
| 01/17/2002 | WO2001046228A3 Nucleic acid vaccination |
| 01/17/2002 | WO2001046222A3 Peptides designed for the diagnosis and treatment of rheumatoid arthritis |
| 01/17/2002 | WO2001044291A3 Polynucleotid encoding the rg1 polypeptide |
| 01/17/2002 | WO2001042299A3 Hepatitis virus sentinel virus i (svi) |
| 01/17/2002 | WO2001041703A3 Method for treating allergic diseases |
| 01/17/2002 | WO2001040446A3 Pour-on formulations |
| 01/17/2002 | WO2001036461A3 Compositions and methods for regulating tumor-associated antigen expression |
| 01/17/2002 | WO2001032696A3 Traf family proteins |
| 01/17/2002 | WO2001031011A3 Gene mining system and method |
| 01/17/2002 | WO2001029192A3 Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses |
| 01/17/2002 | WO2001029078A3 Method for production and use of mite group 1 proteins |
| 01/17/2002 | WO2001027290A3 Aortic carboxypeptidase-like protein and nucleic acids encoding same |
| 01/17/2002 | WO2001027144A3 Ab5 toxin b subunit mutants with altered chemical conjugation characteristics |
| 01/17/2002 | WO2001022972A3 Immunostimulatory nucleic acids |
| 01/17/2002 | WO2001021656A3 Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors |
| 01/17/2002 | WO2001016377A3 Diagnostics and therapeutics for osteoporosis |
| 01/17/2002 | WO2001016174A3 Induction of cytotoxic t lymphocyte response by hla class ia restricted epitopes of mycobacterial heat shock protein 65 |
| 01/17/2002 | WO2001013117A3 Proteins, genes and their use for diagnosis and treatment of breast cancer |
| 01/17/2002 | WO2001012598A3 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
| 01/17/2002 | WO2000078971A3 Atp binding cassette transporter protein abc1 popypeptides |
| 01/17/2002 | WO2000078952A3 Human rna metabolism proteins (rmep) |
| 01/17/2002 | WO2000060077A3 Compounds for therapy and diagnosis of lung cancer and methods for their use |
| 01/17/2002 | US20020007173 Method of inducing a CTL response |
| 01/17/2002 | US20020006905 Use of botulinum toxins for treating various disorders and conditions and associated pain |
| 01/17/2002 | US20020006903 Genetic engineering |
| 01/17/2002 | US20020006899 Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals |
| 01/17/2002 | US20020006662 Preferential aggregation; for use in the treatment of melanomas |
| 01/17/2002 | US20020006654 Isolated cathepsin L type cysteine proteases and reducing intercorneocyte cohesion/promoting desquamation therewith |
| 01/17/2002 | US20020006633 Assay for anti transglutaminase antibodies detection useful in celicac disease diagnosis |
| 01/17/2002 | US20020006630 Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers |
| 01/17/2002 | US20020006413 Stimulating an immune response in a patient having an adenocarcinoma, comprising administering to such patient one or more allogenic tumor cells selected from SW620 cell, COLO 205 cell, and SW403 cell |
| 01/17/2002 | US20020006412 An adenovirus particulate comprising adenovirus particles complexed to an insoluble micro-platform selected from polymeric fiber or microbead; adenovirus particulate comprises a cell binding ligand complexed to microplatform |
| 01/17/2002 | US20020006411 Vaccines expressed in plants |
| 01/17/2002 | US20020006410 Method for treating inflammatory diseases using heat shock proteins |
| 01/17/2002 | US20020006409 Composition and method of cancer antigen immunotherapy |
| 01/17/2002 | US20020006408 Vaccines against eimeria mediated disorder |
| 01/17/2002 | US20020006407 Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability |
| 01/17/2002 | US20020006404 Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| 01/17/2002 | US20020006397 Delivering a cytotoxic agent which is one or more of herpes simplex virus thymidine kinase (HSV-tk), gancicolvir, or a rejection antigen, into a antigenic biniding protein APBP molecule to induce lysis of target cell |
| 01/17/2002 | US20020006392 Isolating peripheral mononuclear blood cells from a recipient and a donor; mixing donor and recipient cells ex vivo, treating the cells with a regulatory composition (TGF-beta) transforming growth factor to activate the cells |
| 01/17/2002 | US20020006391 Genetic engineering |
| 01/17/2002 | US20020006379 Diagnosis of tissue damage, cancer |
| 01/17/2002 | DE10032538A1 Vakzine gegen Helicobacter pylori Vaccine against Helicobacter pylori |
| 01/17/2002 | CA2658217A1 Expression system |
| 01/17/2002 | CA2416224A1 Multiple antigenic peptides immunogenic against streptococcus pneumoniae |
| 01/17/2002 | CA2415902A1 Protein design automation for designing protein libraries with altered immunogenicity |
| 01/17/2002 | CA2415808A1 Transporters and ion channels |
| 01/17/2002 | CA2415544A1 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/17/2002 | CA2415484A1 Human myeloma cell line |
| 01/17/2002 | CA2415100A1 Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
| 01/17/2002 | CA2414926A1 Microspheres and adjuvants for dna vaccine delivery |
| 01/17/2002 | CA2414460A1 Fimh adhesin proteins and methods of use |
| 01/17/2002 | CA2414374A1 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| 01/17/2002 | CA2414272A1 Bifunctional molecules and vectors complexed therewith for targeted gene delivery |
| 01/17/2002 | CA2413045A1 Expression system |
| 01/17/2002 | CA2351110A1 Helicobacter felis vaccine |
| 01/16/2002 | EP1172654A1 Diagnostic method based on the detection of the L1 adhesion molecule for ovarian and endometrial tumors |
| 01/16/2002 | EP1172116A1 Pharmaceutical composition comprising anti-H.pylori urease IgY antibodies and an inhibitor of gastric acid secretion |
| 01/16/2002 | EP1171626A1 50 human secreted proteins |
| 01/16/2002 | EP1171623A2 Production of attenuated negative stranded rna virus vaccines |
| 01/16/2002 | EP1171612A2 Telomerase-specific cancer vaccine |
| 01/16/2002 | EP1171608A2 Recombinant and mutant marek's disease virus |
| 01/16/2002 | EP1171606A2 Nucleic acid vaccines against rickettsial diseases and methods of use |
| 01/16/2002 | EP1171605A1 Peptides and assays for the diagnosis of lyme disease and compositions useful for the prevention thereof |
| 01/16/2002 | EP1171604A2 Dna sequence and recombinant production of a graminae allergen |
| 01/16/2002 | EP1171600A2 Zalpha13: a human secreted protein |
| 01/16/2002 | EP1171599A1 Adipocyte complement related protein homolog zacrp2 |
| 01/16/2002 | EP1171597A2 Prostate-restricted gene 30p3c8 expressed in prostate cancer |
| 01/16/2002 | EP1171595A1 13 transmembrane protein expressed in prostate cancer |
| 01/16/2002 | EP1171587A1 Peptide from antigen muc-1 for triggering an immune response to tumor cells |
| 01/16/2002 | EP1171580A2 Human homologues of fused gene |
| 01/16/2002 | EP1171579A1 Human tumor necrosis factor receptor tr9 |
| 01/16/2002 | EP1171577A2 Anti-bacterial vaccine compositions |
| 01/16/2002 | EP1171469A1 ANTI-p53 ANTIBODIES |
| 01/16/2002 | EP1171468A2 Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment |
| 01/16/2002 | EP1171462A2 49 human secreted proteins |
| 01/16/2002 | EP1171458A1 50 human secreted proteins |
| 01/16/2002 | EP1171457A1 46 human secreted proteins |
| 01/16/2002 | EP1171163A1 Compositions containing tetracyclines for treating hemorrhagic virus infections and other disorders |
| 01/16/2002 | EP1171161A1 Treatment of adult rheumatoid arthritis by oral administration of pooled human immunoglobulin and an antacid |
| 01/16/2002 | EP1171160A1 Method and means for treating post-polio syndrome |
| 01/16/2002 | EP1171159A2 Combination vaccine against streptococcus pneumoniae and respiratory syncytial virus (rsv) |
| 01/16/2002 | EP1171158A2 Vaccine comprising rsv antigen and cpg oligonucleotide |
| 01/16/2002 | EP1171157A2 Use of glucose-6-phospate isomerase and antibodies thereto for the diagnosis and therapy of arthritis, and test of anti-arthritic compounds |
| 01/16/2002 | EP1171156A1 Novel use within transplantation surgery |
| 01/16/2002 | EP1171154A2 Uses of mammalian ox2 protein and related reagents |
| 01/16/2002 | EP1171109A1 Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft |
| 01/16/2002 | EP1171098A1 A method for improving the half-life of soluble viral-specific ligands on mucosal membranes |
| 01/16/2002 | EP1171078A2 Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol |
| 01/16/2002 | EP0896585B1 Humanized anti-cd40 monoclonal antibodies and fragments capable of blocking b cell activation |
| 01/16/2002 | EP0840791B1 Generation of immune responses to prostate-specific antigen (psa) |
| 01/16/2002 | EP0811071B1 Amplifier sequences derived from the desmin gene, vectors comprising same and uses thereof for producing proteins |
| 01/16/2002 | EP0786088B1 Presentation of lipoarabinomannan antigens to t-cells by cd1 molecules |
| 01/16/2002 | EP0742903B1 Piperidine analogs and conjugates of procainamide and napa |
| 01/16/2002 | EP0722344B1 Process for virus deactivation in the presence of a polyether and an agens |